Polycystic Ovarian Syndrome Treatment Market To Reach $6.99 Billion By 2030

Polycystic Ovarian Syndrome Treatment Market Growth & Trends

The global polycystic ovarian syndrome treatment market size is estimated to reach USD 6.99 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery. 

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

 Request a free sample copy or view report summary: Polycystic Ovarian Syndrome Treatment Market Report

Polycystic Ovarian Syndrome Treatment Market Report Highlights

• Based on drug class, the insulin-sensitizing agents dominated the market and accounted for a share of 36.0% in 2024.

• By surgery, the ovarian wedge resection segment is expected to grow at a significant CAGR over the forecast period.

• Based on the distribution channel, the online providers segment is expected to register the fastest CAGR during the forecast period.

• Asia Pacific’s polycystic ovarian syndrome treatment market is estimated to register the fastest CAGR over the forecast period.

Polycystic Ovarian Syndrome Treatment Market Segmentation

Grand View Research has segmented the global polycystic ovarian syndrome treatment market based on drug Class, surgery, distribution channel, and region:

Polycystic Ovarian Syndrome Treatment Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)

• Oral Contraceptives

• Antiandrogens

• Insulin-sensitizing Agent

• Antidepressant

• Anti-obesity

Polycystic Ovarian Syndrome Treatment Surgery Outlook (Revenue, USD Billion, 2018 - 2030)

• Ovarian Wedge Resection

• Laparoscopic Ovarian Drilling

Polycystic Ovarian Syndrome Treatment Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacy

• Drug Store & Retail Pharmacy

• Online Providers

Polycystic Ovarian Syndrome Treatment Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

• Latin America

  • Brazil

• Middle East and Africa (MEA)

  • KSA

  • UAE

  • South Africa

List of Key Players in the Polycystic Ovarian Syndrome Treatment Market

• AstraZeneca

• Bayer AG

• Merck KGaA

• Abbott

• Pfizer, Inc

• Sanofi

• Bristol Myers Squibb Company

• Teva Pharmaceutical Industries Ltd

• Novartis AG

• Ferring B.V.